Evidence map›Paper›PMID 21184675›Full record

Trial reportCritical care (London, England)2010

Lack of effect of glutamine administration to boost the innate immune system response in trauma patients in the intensive care unit.

Jon Pérez-Bárcena, Catalina Crespí, Verónica Regueiro, Pedro Marsé, Joan M Raurich, Jordi Ibáñez, Abelardo García de Lorenzo-Mateos, José A Bengoechea

Registry-linked trialOpen access · goldAbstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Critical care (London, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01250080 (Effect of Gutamine Administration in the Innate Immune System Response in ICU Patients.), which is not on this map. Cited by 18 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 7 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01250080 nacompletednot on this map

Effect of Gutamine Administration in the Innate Immune System Response in ICU Patients.

TypeinterventionalSponsorHospital Universitari Son DuretaRan2007 to 2008Enrolled43ConditionsModerate to Severe Trauma, as Defined by an, Injury Severity Score (ISS) > 12 Points Were Included in the Study.ArmsTotal Parenteral Nutrition with Glutamine, Total Parenteral Nutrition without glutamine
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 7 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Glutamine supplementation for critically ill adults.The Cochrane database of systematic reviews · 2014
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Review
  9. Article
  10. Glutamine supplementation in trauma ICU patients.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2020
    Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Jon Pérez-BárcenaIntensive Care Medicine Department, Son Dureta University Hospital, Andrea Doria 55, 07014, Palma de Mallorca, Spain. juan.perez@ssib.es
Catalina Crespí
Verónica Regueiro
Pedro Marsé
Joan M Raurich
Jordi Ibáñez
Abelardo García de Lorenzo-Mateos
José A Bengoechea
Hospital Universitario Son Dureta · ESCentro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESHospital Universitario La Paz · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe use of glutamine as a dietary supplement is associated with a reduced risk of infection. We hypothesized that the underlying mechanism could be an increase in the expression and/or functionality of Toll-like receptors (TLR), key receptors sensing infections. The objective of this study was to evaluate whether glutamine supplementation alters the expression and functionality of TLR2 and TLR4 in circulating monocytes of trauma patients admitted to the intensive care unit (ICU).

methodsWe designed a prospective, randomized and single-blind study. Twenty-three patients received parenteral nutrition (TPN) with a daily glutamine supplement of 0.35 g/kg. The control group (20 patients) received an isocaloric-isonitrogenated TPN. Blood samples were extracted before treatment, at 6 and 14 days. Expression of TLR2 and TLR4 was determined by flow cytometry. Monocytes were stimulated with TLR specific agonists and cytokines were measured in cell culture supernatants. Phagocytic ability of monocytes was also determined.

resultsBasal characteristics were similar in both groups. Monocytes from patients treated with glutamine expressed the same TLR2 levels as controls before treatment (4.9 ± 3.5 rmfi vs. 4.3 ± 1.9 rmfi, respectively; P = 0.9), at Day 6 (3.8 ± 2.3 rmfi vs. 4.0 ± 1.7 rmfi, respectively; P = 0.7) and at Day 14 (4.1 ± 2.1 rfim vs. 4.6 ± 1.9 rmfi, respectively; P = 0.08). TLR4 levels were not significantly different between the groups before treatment: (1.1 ± 1 rmfi vs 0.9 ± 0.1 rmfi respectively; P = 0.9), at Day 6 (1.1 ± 1 rmfi vs. 0.7 ± 0.4 rmfi respectively; P = 0.1) and at Day 14 (1.4 ± 1.9 rmfi vs. 1.0 ± 0.6 rmfi respectively; P = 0.8). No differences in cell responses to TLR agonists were found between groups. TLR functionality studied by phagocytosis did not vary between groups.

conclusionsIn trauma patients in the intensive care unit, TPN supplemented with glutamine does not improve the expression or the functionality of TLRs in peripheral blood monocytes.

trial registrationClinicalTrials.gov Identifier: NCT01250080.

Indexed as

Intensive Care UnitsAdultFemaleGlutamineHumansImmunity, InnateMaleMiddle AgedProspective StudiesSingle-Blind MethodToll-Like Receptor 4Treatment OutcomeWounds and InjuriesYoung AdultGlutamineTLR4 protein, humanToll-Like Receptor 4

Identifiers

PMID21184675
PMCPMC3219991
OpenAlexW2156776340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.